- McKesson (NYSE: MCK) received a price target of $977.00 from Morgan Stanley, indicating a 6.70% upside from its current share price of $915.45.
- McKesson has agreed to acquire Option Care Health (NASDAQ: OCAH) for $32.05 per share, valuing the deal at approximately $5.80 billion.
- This strategic acquisition expands McKesson's healthcare operations by adding Option Care Health's home-based infusion treatment services.
McKesson (NYSE: MCK) is a major distributor of medicines and medical supplies to pharmacies, hospitals, and other health providers. Erin Wright of Morgan Stanley sets a $977.00 price target for McKesson, compared with a share price of $915.45 when the target is posted. That implies approximately 6.70% upside.
McKesson also has a definitive agreement with investment firm CD&R to acquire Option Care Health (NASDAQ: OCAH), which provides infusion treatments in patients’ homes and other care settings. The purchase price is $32.05 per Option Care Health share.
The deal values Option Care Health at approximately $5.80 billion, including debt. Including debt means the figure reflects more than the price paid for shares; it also accounts for debt tied to the business. The acquisition adds home-based treatment services to McKesson’s existing healthcare operations.
McKesson shares trade at $915.45, up $13.17, or 1.46%. They range from $899.63 to $922.46 today and from $723.68 to $999.00 over the past year. McKesson’s market capitalization—the total value of its shares—is approximately $107.18 billion, and trading volume is 697,614 shares.
